{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:00:43Z","timestamp":1794344443190,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13555-019-00340-3","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T19:02:46Z","timestamp":1574276566000},"page":"133-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure"],"prefix":"10.1007","volume":"10","author":[{"given":"April","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Agada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"9997","key":"340_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"3","key":"340_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"340_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"9","key":"340_CR4","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/eji.201242605","volume":"42","author":"S Cypowyj","year":"2012","unstructured":"Cypowyj S, Picard C, Marodi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol. 2012;42(9):2246\u201354.","journal-title":"Eur J Immunol"},{"issue":"2\u20133","key":"340_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12026-011-8226-x","volume":"50","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011;50(2\u20133):181\u20137.","journal-title":"Immunol Res"},{"issue":"1","key":"340_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1128\/IAI.00929-09","volume":"78","author":"A Peck","year":"2010","unstructured":"Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun. 2010;78(1):32\u20138.","journal-title":"Infect Immun"},{"issue":"6025","key":"340_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","volume":"332","author":"A Puel","year":"2011","unstructured":"Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65\u20138.","journal-title":"Science"},{"issue":"1","key":"340_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65\u201370.","journal-title":"Gut"},{"issue":"12","key":"340_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"6","key":"340_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O\u2019Connor Jr","year":"2009","unstructured":"O\u2019Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603\u20139.","journal-title":"Nat Immunol"},{"issue":"6","key":"340_CR11","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","volume":"140","author":"W Strober","year":"2011","unstructured":"Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756\u201367.","journal-title":"Gastroenterology"},{"issue":"11","key":"340_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"340_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","volume":"19","author":"C Tang","year":"2018","unstructured":"Tang C, Kakuta S, Shimizu K, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol. 2018;19(7):755\u201365.","journal-title":"Nat Immunol"},{"issue":"2","key":"340_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","volume":"35","author":"S Taleb","year":"2015","unstructured":"Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015;35(2):258\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9993","key":"340_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"340_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014\u201323.","journal-title":"Br J Dermatol"},{"issue":"3","key":"340_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","volume":"76","author":"B Strober","year":"2017","unstructured":"Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"340_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.15242","volume":"33","author":"RG Langley","year":"2019","unstructured":"Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"340_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"4","key":"340_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352.","journal-title":"Br J Dermatol"},{"issue":"10","key":"340_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/gut.35.10.1433","volume":"35","author":"C Gower-Rousseau","year":"1994","unstructured":"Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988\u20131990). Gut. 1994;35(10):1433\u20138.","journal-title":"Gut"},{"issue":"3","key":"340_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"340_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"340_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"340_CR25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5\u00a0years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"1","key":"340_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.17084","volume":"180","author":"C Leonardi","year":"2019","unstructured":"Leonardi C, Papp K, Strober B, et al. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2019;180(1):76\u201385.","journal-title":"Br J Dermatol"},{"issue":"4","key":"340_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.16798","volume":"179","author":"F Valenzuela","year":"2018","unstructured":"Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179(4):853\u201362.","journal-title":"Br J Dermatol"},{"issue":"2","key":"340_CR28","first-page":"200","volume":"17","author":"NH Shear","year":"2018","unstructured":"Shear NH, Paul C, Blauvelt A, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol. 2018;17(2):200\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"14","key":"340_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735\u201341.","journal-title":"JAMA"},{"issue":"4","key":"340_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","volume":"159","author":"JA Kaye","year":"2008","unstructured":"Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895\u2013902.","journal-title":"Br J Dermatol"},{"issue":"8","key":"340_CR31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research database. Eur Heart J. 2010;31(8):1000\u20136.","journal-title":"Eur Heart J"},{"issue":"8","key":"340_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775\u20136.","journal-title":"Am J Med"},{"issue":"3","key":"340_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol. 2010;163(3):586\u201392.","journal-title":"Br J Dermatol"},{"issue":"9","key":"340_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, von Wyler BM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362\u201370.","journal-title":"Am J Cardiol"},{"issue":"3","key":"340_CR35","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","volume":"50","author":"SL Westlake","year":"2011","unstructured":"Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50(3):518\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"340_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295\u2013307.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"340_CR37","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jdv.14951","volume":"32","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, Joshi AA, Reddy SP, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1320\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"340_CR38","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","volume":"165","author":"K Abuabara","year":"2011","unstructured":"Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066\u201373.","journal-title":"Br J Dermatol"},{"issue":"5","key":"340_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","volume":"12","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321\u201337.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"340_CR40","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/jid.2009.113","volume":"129","author":"YB Brauchli","year":"2009","unstructured":"Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case\u2013control analysis. J Invest Dermatol. 2009;129(11):2604\u201312.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"340_CR41","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3899\/jrheum.100041","volume":"37","author":"MS Krathen","year":"2010","unstructured":"Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37(11):2205\u201315.","journal-title":"J Rheumatol"},{"issue":"2","key":"340_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","volume":"140","author":"G Frentz","year":"1999","unstructured":"Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999;140(2):237\u201342.","journal-title":"Br J Dermatol"},{"issue":"6","key":"340_CR43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","volume":"60","author":"RV Patel","year":"2009","unstructured":"Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"340_CR44","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","volume":"66","author":"KA Papp","year":"2012","unstructured":"Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"340_CR45","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","volume":"353","author":"AI Rubin","year":"2005","unstructured":"Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262\u20139.","journal-title":"N Engl J Med"},{"key":"340_CR46","doi-asserted-by":"publisher","unstructured":"Grace E, Zhu B, Malley W, et al. Safety events occurring among patients exposed to ixekizumab in the Corrona Psoriasis Registry. Poster presented at: 6th Congress of the Skin Inflammation and Psoriasis International Network; 25\u201327 April 2019; Paris, France. J Eur Acad Dermatol Venereol 33[S3]:P001. https:\/\/doi.org\/10.1111\/jdv.15512.","DOI":"10.1111\/jdv.15512"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-019-00340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-019-00340-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-019-00340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T14:07:13Z","timestamp":1710684433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-019-00340-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1007\/s13555-019-00340-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}